Current approaches to generate core–shell nanoparticles for biomedical applications are limited by factors such as synthetic scalability and circulatory desorption of cytotoxic surfactants. Developments in controlled radical polymerization, particularly in dispersed states, represent a promising method of overcoming these challenges. In this work, well-defined PEGylated nanoparticles are synthesized using reversible addition fragmentation chain transfer emulsion polymerization to control particle size and surface composition and were further characterized with light scattering, electron microscopy, and size exclusion chromatography. Importantly, the nanoparticles are found to be tolerated both in vitro and in vivo, without the need for any purification after particle synthesis. Pharmacokinetic and biodistribution studies in mice, following intraperitoneal injection of the nanoparticles, reveal a long (>76 h) circulation time and accumulation in the liver.
Bibliographical noteFunding Information:
The authors thank CRUK/EPSRC (C53561/A19933; P.G., C.S.-C., K.A., H.X.-M., F.L., S.P.), the German Research Foundation (DFG, GZ; HA 7725/1-1; M.H.), the Warwick Innovation Fund (R.D.), and the Royal Society Wolfson Merit Award (WM130055; S.P.) for financial support. The authors are grateful to LICOR Inc. for access to a Pearl Trilogy imaging system for in vivo experiments. The staff of the BSU at Warwick are thanked for animal husbandry.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
- biocompatible nanoparticles
- reversible addition fragmentation chain transfer emulsion polymerization
- tunable nanoparticles